Tyverb still not cost-effective for breast cancer, says NICE
This article was originally published in Scrip
Executive Summary
NICE, the UK's National Institute for health and Clinical Excellence, maintains that GlaxoSmithKline's Tyverb (lapatinib) is not cost-effective and should not be used to treat previously treated women with advanced or metastatic breast cancer on the NHS in England and Wales.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.